%0 Journal Article
%A Yaromina, Ala
%A Koi, Lydia
%A Schuitmaker, Lesley
%A van der Wiel, Alexander M A
%A Dubois, Ludwig J
%A Krause, Mechthild
%A Lambin, Philippe
%T Overcoming radioresistance with the hypoxia-activated prodrug CP-506: a pre-clinical study of local tumour control probability.
%J Radiotherapy and oncology
%V 186
%@ 0167-8140
%C Amsterdam [u.a.]
%I Elsevier Science
%M DKFZ-2023-01180
%P 109738
%D 2023
%Z Volume 186, September 2023, 109738
%X Tumour hypoxia is an established radioresistance factor. A novel hypoxia-activated prodrug CP-506 has been proven to selectively target hypoxic tumour cells and to cause anti-tumour activity. The current study investigates whether CP-506 improves outcome of radiotherapy in vivo.Mice bearing FaDu and UT-SCC-5 xenografts were randomized to receive 5 daily injections of CP-506/vehicle followed by single dose (SD) irradiation. In addition, CP-506 was combined once per week with fractionated irradiation (30 fractions/6 weeks). Animals were followed-up to score all recurrences. In parallel, tumours were harvested to evaluate pimonidazole hypoxia, DNA damage (γH2AX), expression of oxidoreductases.CP-506 treatment significantly increased local control rate after SD in FaDu, 62
%K Hypoxia (Other)
%K Hypoxia-activated prodrug CP-506 (Other)
%K Radiotherapy (Other)
%K local control (Other)
%K xenografts (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37315579
%R 10.1016/j.radonc.2023.109738
%U https://inrepo02.dkfz.de/record/276868